Literature DB >> 23452955

Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide.

Pablo N De Francesco1, Juan M Mucci, Romina Ceci, Carlos A Fossati, Paula A Rozenfeld.   

Abstract

Fabry disease is an X-linked lysosomal disorder (LD) due to deficiency of the enzyme α-galactosidase A (αGal), which leads to the accumulation of neutral glycosphingolipids, mainly globotriaosylceramide (Gb3). Several mechanisms contribute to the diverse physiopathological alterations observed in this disease, and it has been suggested that an underlying proinflammatory state could play a significant role. The aim of this study is to investigate the presence of a proinflammatory state in the different subsets of peripheral blood mononuclear cells (PBMC) and to understand the mechanisms that contribute to its onset and perpetuation. We have shown that cultured PBMC from Fabry patients present a higher proinflammatory cytokine expression and production. Moreover, we determined that among PBMC, dendritic cells and monocytes present a basal proinflammatory cytokine production profile, which is further exacerbated with an inflammatory stimulus. Finally we established that normal, monocyte-derived dendritic cells and macrophages display the same proinflammatory profile when cultured in the presence of Gb3 and an inhibitor of αGal. Furthermore, this effect can be abolished using a TLR4 blocking antibody, indicating that TLR4 is necessary in the process. In summary, our results demonstrate the presence of a proinflammatory state involving two key subsets of innate immunity, and provide direct evidence of Gb3 having a proinflammatory role, likely mediated by TLR4, a finding that could help in the understanding of the underlying causes of the inflammatory pathogenesis of Fabry disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23452955     DOI: 10.1016/j.ymgme.2013.02.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

1.  Age at First Cardiac Symptoms in Fabry Disease: Association with a Chinese Hotspot Fabry Mutation (IVS4+919G>A), Classical Fabry Mutations, and Sex in a Taiwanese Population from the Fabry Outcome Survey (FOS).

Authors:  Hao-Chuan Liu; Amandine Perrin; Ting-Rong Hsu; Chia-Feng Yang; Hsiang-Yu Lin; Wen-Chung Yu; Dau-Ming Niu
Journal:  JIMD Rep       Date:  2015-03-12

2.  Evidence for inflammation in Fabry's disease? Headache and muscle involvement responding to corticosteroid and methotrexate treatment.

Authors:  Markus Kraemer; N Karabul; P Berlit; A Rolfs
Journal:  J Neurol       Date:  2017-01-27       Impact factor: 4.849

3.  Innate and Adaptive Immune Response in Fabry Disease.

Authors:  Wladimir Mauhin; Olivier Lidove; Elisa Masat; Federico Mingozzi; Kuberaka Mariampillai; Jean-Marc Ziza; Olivier Benveniste
Journal:  JIMD Rep       Date:  2015-02-18

4.  Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST).

Authors:  Osamu Saito; Eiji Kusano; Tetsu Akimoto; Yasushi Asano; Teruo Kitagawa; Ken Suzuki; Nobuyuki Ishige; Takashi Akiba; Akira Saito; Eiji Ishimura; Motoshi Hattori; Akira Hishida; Chu Guili; Hiroki Maruyama; Masahisa Kobayashi; Touya Ohashi; Ichiro Matsuda; Yoshikatsu Eto
Journal:  Clin Exp Nephrol       Date:  2015-07-22       Impact factor: 2.801

5.  Elevated Endomyocardial Biopsy Macrophage-Related Markers in Intractable Myocardial Diseases.

Authors:  Yuka Hayashi; Haruo Hanawa; Shuang Jiao; Go Hasegawa; Yukako Ohno; Kaori Yoshida; Tomoyasu Suzuki; Takeshi Kashimura; Hiroaki Obata; Komei Tanaka; Tohru Watanabe; Tohru Minamino
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 6.  The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.

Authors:  A Broomfield; S A Jones; S M Hughes; B W Bigger
Journal:  J Inherit Metab Dis       Date:  2016-02-16       Impact factor: 4.982

Review 7.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

Review 8.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

9.  Frequency of Fabry disease in a juvenile idiopathic arthritis cohort.

Authors:  Luciana Paim-Marques; Amanda Virginia Cavalcante; Islane Verçosa; Paula Carneiro; Marcia Souto-Maior; Erlane Marques; Simone Appenzeller
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-12       Impact factor: 3.054

10.  Increased Serum Interleukin-6 and Tumor Necrosis Factor Alpha Levels in Fabry Disease: Correlation with Disease Burden.

Authors:  Nilton Salles Rosa Neto; Judith Campos de Barros Bento; Valéria de Falco Caparbo; Rosa Maria Rodrigues Pereira
Journal:  Clinics (Sao Paulo)       Date:  2021-07-16       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.